ReviewCureus2026
MicroRNA Signatures in Cardiovascular Diseases: A Systematic Literature Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases remain the leading contributors to global morbidity and mortality, and current diagnostic and prognostic tools do not fully capture disease-specific molecular changes. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are increasingly being investigated as stable circulating biomarkers in cardiovascular disorders. This systematic review aimed to qualitatively synthesise evidence on microRNA signatures associated with cardiovascular diseases and evaluate their diagnostic, prognostic, predictive, severity-related, and treatment-response relevance. A systematic search was conducted in PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, and Google Scholar using microRNA-, cardiovascular disease-, and biomarker-related terms. Original studies reporting extractable microRNA findings in cardiovascular disease populations or clinically relevant translational models with human validation were included. Review articles were used only for background context. Eleven eligible studies were qualitatively synthesised; no meta-analysis was performed because of heterogeneity in cardiovascular phenotypes, biospecimens, analytical platforms, and outcomes. The review found that plasma and serum microRNA signatures were associated with acute myocardial infarction, coronary artery disease, postoperative atrial fibrillation, heart failure, HFpEF, pulmonary arterial hypertension, coronary artery calcification, and cardiovascular risk burden. Multi-microRNA panels generally showed stronger clinical performance than single markers. The evidence base was limited by heterogeneity in study populations, cardiovascular phenotypes, biospecimen sources, miRNA extraction and profiling platforms, normalisation approaches, outcome definitions, and limited standardisation across miRNA platforms. Overall, microRNA signatures represent promising minimally invasive biomarkers for cardiovascular disease characterisation, although standardised validation remains essential before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.